GlassScriptPhysician profile
Edith M Rayfield
NPI 1831181759
$3,660.20
in general payments reported to CMS, 2019-2025
17 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $353 · 2021: $78.02 · 2022: $663 · 2023: $557 · 2024: $641 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,290.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,019.01 | 2019-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $998.84 | 2020-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $449.50 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $340.73 | 2024-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $186.23 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $156.41 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $138.44 | 2019-2020 | |
| Glaxosmithkline, LLC. | $120.21 | 2024-2025 | Arexvy, Shingrix, Penmenvy |
| Pfizer INC. | $62.21 | 2022-2025 | |
| Topcon Healthcare Solutions, INC. | $42.58 | 2019 | |
| Gilead Sciences, INC. | $30.42 | 2025 | |
| Tms Neurohealth Centers INC. | $22.73 | 2025 | Tms Neurohealth Centers INC. |
| Abbott Laboratories | $21.41 | 2022 | |
| Vanda Pharmaceuticals INC. | $20.13 | 2022 | |
| Dexcom, INC. | $19.64 | 2024 | Dexcom G6 Transmitter |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $17.13 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $14.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edith Rayfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.